CVS Health is still “coming back,” and one analyst argues the stock’s valuation has not caught up

CVS Health continues to live in the space between turnaround hopes and market skepticism, and a recent market commentary argues the gap may be wider than investors think. In a June 16 post syndicated on Yahoo Finance, the author frames the company’s “comeback” as not fully underway, while suggesting the valuation remains unusually low compared with the progress that has already been made.

The piece also makes a direct valuation argument, telling readers that it may not be “too late” to participate in the shift in expectations. While the post’s title emphasizes “shockingly cheap” valuation, it does not, in the information available here, provide a detailed breakdown of the specific valuation measures it uses or how it compares CVS to peers or to its own history.

CVS Health is a major U.S. healthcare distributor and insurer, with revenue tied to how well it can manage pharmacy services, pricing and reimbursement dynamics, and the costs of providing care through its insurance businesses. In that context, a “comeback” narrative generally depends on measurable improvements such as medical cost trends, administrative efficiency, pharmacy margin resilience, or capital allocation decisions. However, the details that would normally support those points are not available in the excerpted material provided with this task.

The commentary’s framing matters less as a precise model and more as a announcement of investor sentiment. When valuation is described as “cheap” while a turnaround is described as “just getting started,” it implies the author believes the market has not yet fully priced in operating stabilization or a return to stronger performance. It also implies that the author sees remaining upside, or at least less downside than the current price suggests.

Still, the absence of disclosed specifics is important. Without the post’s full discussion, it is not possible to confirm which financial metrics the author points to, such as forward earnings multiples, free cash flow expectations, or any segment-by-segment improvement. It also is not possible to verify whether the author attributes the turnaround to policy changes, competitive dynamics in pharmacy benefit management, insurance underwriting improvements, or any particular operational reform.

For CVS Health, the company’s near-term path typically hinges on a few industry-wide variables that investors closely watch: pharmacy benefit management profitability, Medicare Advantage and other insurance risk trends, government reimbursement pressures, and the pace of healthcare utilization. In addition, any turnaround narrative must contend with the reality that healthcare earnings can be influenced by factors outside management control, including regulatory adjustments and shifting patient demand.

What to watch next is whether CVS begins to demonstrate consistent improvement that is visible in quarterly results, guidance, and cash generation, rather than only in market commentary. If additional investor-facing materials or earnings updates reinforce the idea that the comeback is early, the valuation debate may shift from opinion to evidence.

If the commentary is correct, the market would eventually have to reconcile an “early-stage” turnaround claim with observable financial progress. If it is not, the same valuation argument could prove premature, especially if underlying cost pressures persist or if reimbursement and utilization trends move against the company.